Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.
about
Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug.How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?Reducing QT liability and proarrhythmic risk in drug discovery and development.On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex.Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels.hERG subunit composition determines differential drug sensitivity.Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity.On-chip constructive cell-network study (II): on-chip quasi-in vivo cardiac toxicity assay for ventricular tachycardia/fibrillation measurement using ring-shaped closed circuit microelectrode with lined-up cardiomyocyte cell networkAn infrared optical pacing system for screening cardiac electrophysiology in human cardiomyocytes.An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment.Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium.
P2860
Q33635283-3E3C08F3-27C9-4561-BFAC-724C29EE3D32Q35036150-FC30BD48-F756-4CC7-87CD-E94A11B14144Q37689199-C6B1A1B6-ABF2-4193-9E3B-9EBF21EEAAB8Q38464799-DD2677EF-26D4-4A95-97C4-3382C47DB884Q38529440-81E96F19-9E68-41EA-960D-C8795645628CQ38649960-0204C812-2D30-42C4-A059-5E0583F2E90FQ39211305-C66EFBCE-E258-4489-8217-9234011DF5A7Q39389524-FB4DB308-16CE-4147-AA61-1F79FD4A1A5FQ41512444-344FD734-81D3-48E9-90D5-E014BFE6B971Q45042887-1544088D-3109-433C-A1D6-611E02E85912Q48225419-404FBC3D-F9AC-4042-BA96-365D45DC091D
P2860
Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Value of non-clinical cardiac ...... evelopment of safer medicines.
@en
Value of non-clinical cardiac ...... evelopment of safer medicines.
@nl
type
label
Value of non-clinical cardiac ...... evelopment of safer medicines.
@en
Value of non-clinical cardiac ...... evelopment of safer medicines.
@nl
prefLabel
Value of non-clinical cardiac ...... evelopment of safer medicines.
@en
Value of non-clinical cardiac ...... evelopment of safer medicines.
@nl
P2093
P2860
P1476
Value of non-clinical cardiac ...... evelopment of safer medicines.
@en
P2093
Chris Pollard
Jean-Pierre Valentin
Pierre Lainée
Tim Hammond
P2860
P356
10.1111/J.1476-5381.2009.00530.X
P407
P577
2010-01-01T00:00:00Z